Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 237.43%.

  • CytomX Therapeutics' EBITDA Margin fell 2547200.0% to 237.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.71%, marking a year-over-year increase of 137100.0%. This contributed to the annual value of 23.03% for FY2024, which is 235100.0% up from last year.
  • Per CytomX Therapeutics' latest filing, its EBITDA Margin stood at 237.43% for Q3 2025, which was down 2547200.0% from 0.64% recorded in Q2 2025.
  • CytomX Therapeutics' EBITDA Margin's 5-year high stood at 49.52% during Q4 2024, with a 5-year trough of 361.26% in Q1 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 25.99% (2024), whereas its average is 118.5%.
  • In the last 5 years, CytomX Therapeutics' EBITDA Margin plummeted by -3213300bps in 2021 and then skyrocketed by 3472400bps in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' EBITDA Margin stood at 315.46% in 2021, then surged by 87bps to 39.61% in 2022, then soared by 109bps to 3.74% in 2023, then skyrocketed by 1224bps to 49.52% in 2024, then crashed by -579bps to 237.43% in 2025.
  • Its EBITDA Margin was 237.43% in Q3 2025, compared to 0.64% in Q2 2025 and 46.15% in Q1 2025.